Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company focused on developing novel oral therapies for neurologic diseases, announced the appointment of Jon Congleton to its Board of Directors, effective March 27, 2026. Mr. Congleton brings nearly 40 years of experience in the biopharmaceutical industry, having held leadership roles in various organizations, including his current position as CEO of Mineralys Therapeutics, Inc. His extensive background includes significant contributions to the launch of Copaxone®, a leading treatment for multiple sclerosis, during his tenure at Teva Pharmaceuticals. As a Class II director, Congleton's term will last until the company's 2028 annual meeting of stockholders. He will also serve as Chair of the Compensation Committee. In connection with his appointment, Congleton received an option grant to purchase 500,000 shares of Immunic's common stock, which will vest over three years, subject to shareholder approval of an increase in shares reserved under the company's equity incentive plan. This strategic addition to the board is expected to enhance Immunic's leadership as it advances its lead development program, vidofludimus calcium, through pivotal clinical milestones and toward potential regulatory approval. The company anticipates top-line data from its phase 3 clinical trials for relapsing multiple sclerosis by the end of 2026, positioning it for significant growth in the market for neurologic therapies.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.